Fintel reports that on June 14, 2024, Maxim Group initiated coverage of Rani Therapeutics Holdings (NasdaqGM:RANI) with a Buy recommendation.
Analyst Price Forecast Suggests 167.56% Upside
As of June 12, 2024, the average one-year price target for Rani Therapeutics Holdings is 10.78. The forecasts range from a low of 8.08 to a high of $14.70. The average price target represents an increase of 167.56% from its latest reported closing price of 4.03.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Rani Therapeutics Holdings is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -1.76.
What is the Fund Sentiment?
There are 51 funds or institutions reporting positions in Rani Therapeutics Holdings. This is an increase of 4 owner(s) or 8.51% in the last quarter. Average portfolio weight of all funds dedicated to RANI is 0.04%, an increase of 2.79%. Total shares owned by institutions increased in the last three months by 5.82% to 3,297K shares. 
The put/call ratio of RANI is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 519K shares representing 1.97% ownership of the company. No change in the last quarter.
Nan Fung Group Holdings holds 494K shares representing 1.88% ownership of the company. No change in the last quarter.
United Services Automobile Association holds 481K shares representing 1.83% ownership of the company. No change in the last quarter.
Alphabet holds 448K shares representing 1.71% ownership of the company. No change in the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 148K shares representing 0.56% ownership of the company. In its prior filing, the firm reported owning 114K shares , representing an increase of 23.42%. The firm increased its portfolio allocation in RANI by 15.00% over the last quarter.
Rani Therapeutics Holdings Background Information
(This description is provided by the company.)
Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
